Ferrer, a B Corp-certified pharmaceutical company, has initiated a Phase II clinical trial, PROSPER, to assess the safety and efficacy of FNP-223 in slowing the progression of Progressive Supranuclear Palsy (PSP).
PROSPER is a randomized, double-blind, placebo-controlled trial involving up to 220 participants across sites in the United States, the United Kingdom, and the European Union.
PSP is a rare neurodegenerative disease characterized by difficulty speaking, imbalance, cognitive issues, and impaired eye control. Currently, there is no cure, but treatments aim to alleviate symptoms.
The cause of PSP is unknown, but it is believed to be associated with the abnormal accumulation of tau protein in certain brain areas. FNP-223 has shown promise in preventing this accumulation in preclinical models.
Ferrer hopes to demonstrate that FNP-223 is safe and effective in PSP patients, potentially slowing the disease’s progression.
Jorge Cúneo, Chief Medical Officer of Ferrer, emphasizes the company’s commitment to improving the lives of individuals with rare diseases. Patient associations CurePSP and PSPA UK have played a role in designing the PROSPER trial.
Kristophe Diaz, Executive Director and Chief Science Officer of CurePSP, highlighted the importance of PROSPER for finding treatments for PSP, a currently incurable condition.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
